Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Intangibles: 2011-2025

Historic Intangibles for RedHill Biopharma (RDHL) over the last 12 years, with Jun 2025 value amounting to $5.5 million.

  • RedHill Biopharma's Intangibles fell 0.56% to $5.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.5 million, marking a year-over-year decrease of 0.56%. This contributed to the annual value of $5.5 million for FY2024, which is 0.56% down from last year.
  • Latest data reveals that RedHill Biopharma reported Intangibles of $5.5 million as of Q2 2025, which was down 0.29% from $5.5 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Intangibles registered a high of $89.4 million during Q4 2021, and its lowest value of $5.5 million during Q2 2025.
  • For the 3-year period, RedHill Biopharma's Intangibles averaged around $5.6 million, with its median value being $5.6 million (2023).
  • In the last 5 years, RedHill Biopharma's Intangibles soared by 10,445.59% in 2021 and then slumped by 93.76% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Intangibles stood at $89.4 million in 2021, then remained steady at $89.4 million in 2022, then crashed by 93.76% to $5.6 million in 2023, then declined by 0.56% to $5.5 million in 2024, then decreased by 0.56% to $5.5 million in 2025.
  • Its Intangibles stands at $5.5 million for Q2 2025, versus $5.5 million for Q4 2024 and $5.6 million for Q2 2024.